Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas

Condition:   Thyroid Cancer Metastatic
Intervention:   Drug: Lenvatinib + Denosumab
Sponsor:   Centre Leon Berard
Not yet recruiting

https://ift.tt/2PGmKHm